The CFR report 'The Pharma Choke Point' provides the first comprehensive analysis showing that U.S. dependence on Chinese pharmaceutical supply chains is structural, not just market-driven, and poses a deliberate weaponization risk similar to rare earths.

U.S. pharmaceutical companies, especially those relying on Chinese-sourced generic APIs, biologics manufacturing, and synthetic DNA; also BD teams, investors, and policymakers assessing supply chain risk.

What should teams watch next?

Watch for policy responses from the U.S. government, potential export controls or tariffs on Chinese pharma inputs, and corporate diversification moves by major pharma companies.

The Pharma Choke Point: Strategic Risk for U.S. Pharma

The Pharma Choke Point: A Strategic Risk for U.S. Pharmaceutical Supply Chains

0% citation coverage1 regulatory sources1 peer-reviewed sources

The Council on Foreign Relations' 'The Pharma Choke Point' report details how U.S. dependence on Chinese pharmaceutical inputs is structural and growing, posing a risk of deliberate supply disruption. This article explains the key findings, implications for pharma teams, and what to watch next.

Dr. Yuki Tanaka MD, PhD · APAC Regulatory Correspondent

Reviewed by Dr. Sarah Chen Pharmaceutical Sciences Editor

Friday, June 5, 2026 5 min read Updated Jun 5, 2026 Your watchlist

Executive Summary

The CFR report The Pharma Choke Point identifies a structural U.S. dependence on Chinese pharmaceutical and biotechnology supply chains, driven by decades of Chinese state investment rather than market forces alone.

This dependence extends beyond generics into biologics manufacturing, first-in-human clinical trials, and synthetic DNA.

China has a history of weaponizing supply chain concentration, as with rare-earth critical minerals, and the same risk now applies to essential medicines.

Show 2 more takeaways

The report provides an archetype model to help policymakers and companies anticipate and mitigate potential disruptions from deliberate Chinese export controls outside of a military conflict or public health emergency.
Immediate risk is highest for essential medicines directly exported from China, such as medications to prevent organ transplant rejections.

Regulatory	medium
Commercial	medium
Competitive	high
Investment	medium

Regulatory

medium

Commercial

medium

Competitive

high

Investment

medium

The Pharma Choke Point: A Strategic Risk for U.S. Pharmaceutical Supply Chains

The Council on Foreign Relations' The Pharma Choke Point report details how U.S. dependence on Chinese pharmaceutical inputs is structural and growing, posing a risk of deliberate supply disruption. This article explains the key findings, implications for pharma teams, and what to watch next.

Key Takeaways

The CFR report The Pharma Choke Point identifies a structural U.S. dependence on Chinese pharmaceutical and biotechnology supply chains, driven by decades of Chinese state investment rather than market forces alone.
This dependence extends beyond generics into biologics manufacturing, first-in-human clinical trials, and synthetic DNA.
China has a history of weaponizing supply chain concentration, as with rare-earth critical minerals, and the same risk now applies to essential medicines.
The report provides an archetype model to help policymakers and companies anticipate and mitigate potential disruptions from deliberate Chinese export controls outside of a military conflict or public health emergency.
Immediate risk is highest for essential medicines directly exported from China, such as medications to prevent organ transplant rejections.

What changed with the release of this report?

On June 3, 2026, the Council on Foreign Relations released a major policy report titled The Pharma Choke Point: How to Reduce U.S. Dependence on Chinese Pharmaceutical and Biotechnology Supply Chains. Authored by Thomas J. Bollyky, Rush Doshi, Prashant Yadav, Olivia Kosloff, and Elena Every, the report is the result of a year-long study group convened by CFR’s Global Health Program and the China Strategy Initiative. It concludes that U.S. dependence on China for essential medicines is structural—deeper, broader, and more consequential than conventional market analyses suggest. That dependence began with generic medicines and their ingredients but is now growing in biologics manufacturing, first-in-human trials, and synthetic DNA. The report warns that the United States faces a growing risk that China will deliberately withhold essential pharmaceutical inputs as a tool of economic or political coercion, as China has done with rare-earth critical minerals. Those risks are greatest for the subset of essential medicines and inputs that China exports directly, which include medications to prevent organ transplant rejections and broad-spectrum antibiotics.

Why this report matters for pharma BD and strategy teams

For BD teams, analysts, and strategy professionals, this report signals a need to reassess supply chain risk exposure. Companies reliant on Chinese-sourced APIs, intermediates, or biologics manufacturing should evaluate alternative sourcing options and consider inventory buffers. Investors should monitor policy developments that could lead to tariffs, export controls, or incentives for domestic production. The report's archetype model offers a framework for scenario planning. Key areas to watch include U.S. government actions to reduce dependence, corporate diversification announcements, and any signs of Chinese export restrictions on pharma inputs. The FDA's drug shortage database already tracks disruptions tied to single-source suppliers, and the report suggests that the agency's current tools may be insufficient for a deliberate, coordinated cutoff.

How does this risk compare to other supply chain vulnerabilities?

In military strategy, a choke point is a geographical feature that restricts movement and access. The CFR report applies this concept to the pharmaceutical supply chain, identifying the limited interface points where U.S. access to essential medicines depends on inputs controlled by China. The report argues that this dependence is not simply the result of market conditions but rather decades of Chinese state investment, making it a strategic vulnerability comparable to the "rare earths" challenge already posed by China’s exploitation of its dominance of those critical minerals. The choke point concept from computer science also applies: a single limited interface where movement and access can be monitored and controlled. The CFR report argues this pattern is now extending into more complex biologics, not just generics.

Frequently Asked Questions

What are the highest-risk medicines identified in the report?

The report identifies that risks are greatest for essential medicines and inputs that China exports directly, which include medications to prevent organ transplant rejections and broad-spectrum antibiotics. The dependence extends beyond generics into biologics manufacturing, first-in-human trials, and synthetic DNA.

How can companies mitigate the risk identified in the report?

Companies should evaluate alternative sourcing options for Chinese-sourced APIs, intermediates, and biologics manufacturing, consider building inventory buffers, and use the report's archetype model for scenario planning. Monitoring U.S. government policy developments on tariffs, export controls, and domestic production incentives is also critical.

Is this risk limited to a military conflict scenario?

No. The report specifically warns that China could deliberately withhold essential pharmaceutical inputs as a tool of economic or political coercion outside of a military conflict, public health emergency, or natural disaster, as it has done with rare-earth critical minerals.

Who authored the CFR report?

The report was authored by Thomas J. Bollyky, Rush Doshi, Prashant Yadav, Olivia Kosloff, and Elena Every, and represents the efforts of a year-long study group convened by CFR’s Global Health Program and the China Strategy Initiative.